UpSwinG: Real-world, non-interventional cohort study on TKI activity in patients with EGFRm NSCLC with uncommon mutations

PIPSeN trial: Olaparib maintenance vs placebo in platinum-sensitive non-small cell lung cancer

Efficacy and early discontinuation predictors in NSCLC patients receiving nivolumab

Language and understanding: The complexity of insight in cancer care

Understanding patient experience in Europe: The first Global Lung Cancer Coalition Patient Experience Survey

CONVERT trial: Patterns of relapse following thoracic radiotherapy in patients with limited-stage SCLC

First-line osimertinib in EGFR mutant aNSCLC patients: Progression pattern and safety in the real-world

AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer

CheckMate 9LA: First-line nivolumab, ipilimumab and 2 cycles chemotherapy vs 4 cycles chemo in aNSCLC

First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407

MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II-III NSCLC

Cemiplimab plus ipilimumab for advanced NSCLC

Autologous tumour infiltrating lymphocytes cell therapy in metastatic non-small cell lung cancer

Incorporating KRAS as a novel biomarker: Challenges and opportunities

Real world data and diagnostics in patients with NSCLC with EGFR exon 20 insertions

Durvalumab following radiotherapy in patients with unresectable, stage 3 NSCLC ineligible for chemotherapy